Vaccine development has become the main tool for reducing COVID-19 cases and the severity of the disease. Comparative analyses of adaptive immunity generated by different vaccines platforms are urgently needed. Multiple studies have compared different vaccines using similar platforms; however, comparative analyses of vaccines across different platforms are lacking. This Editorial provides a summary and commentary on the main findings reported in the observational and longitudinal study by Vályi-Nagy et al. (Geroscience 43:2321) that compared the adaptive (humoral and T cell-mediated) immune responses elicited by Sinopharm and BNT162b2 vaccines against SARS-CoV-2 virus among 57 healthy adult Hungarian volunteers.

疫苗开发已成为减少 COVID-19 病例和疾病严重程度的主要工具。迫切需要对不同疫苗平台产生的适应性免疫进行比较分析。多项研究使用相似的平台比较了不同的疫苗；然而，缺乏跨不同平台的疫苗比较分析。本社论对 Vályi-Nagy 等人在观察性和纵向研究中报告的主要发现进行了总结和评论。( Geroscience 43:2321) 比较了国药和 BNT162b2 疫苗在 57 名健康的匈牙利成年志愿者中针对 SARS-CoV-2 病毒引发的适应性（体液和 T 细胞介导的）免疫反应。